Abstract: The aim of this study is to investigate investigate the expression and clinical significance of RBM15 of N6-methyladenosine（m6 A） modified genes in cervical cancer, three cervical cancer mRNA expression data sets were downloaded from the GEO database, and the expression of m6 A-related genes（METTL3, METTL14, METTL16, WTAP, KIAA1429, RBM15, ZC3H13, FTO, ALKBH5, YTHDF1/2/3, YTHDC1, HNRNPA2B1, HNRNPC） in cervical cancer was screened out. This study made some bioinformatics analysis of RBM15, including UALCAN analysis of relationship between RBM15 expression and multiple clinicopathological features, Linkedomics database was used for RBM15 correlation co-expression gene analysis, and STRING was used for constructing protein-protein interaction network（PPI）, and finally using Kaplan-Meier Plotter database to analyze the relationship between RBM15 and the prognosis of cervical cancer patients. The GEO database difference analysis showed that the expression of RBM15 in cervical cancer was an increasing trend（P＜0.01）, the expression of UALCAN analysis was related to multiple clinicopathological features（P＜0.05）. The Linkedomics analysis showed that 460 genes were positively correlated with RBM15,750 genes were negatively correlated（FDR＜0.05）, and the RBM15 protein interaction network was constructed in STRING. The results of survival analysis showed that the median overall survival time of cervical cancer in the RBM15 gene low expression group was higher than that of the high expression group, but the difference was not statistically significant（HR=1.32, P=0.24）. This study screened the differential expression of m6 A-related genes in cervical cancer, and provided a new idea for the analysis of RBM15 role in cervical cancer by further bioinformatics analysis.